Feb 22, 2018 8:30am EST Benitec Biopharma reports financial results for the 2018 fiscal second quarter and provides operational update
Jan 16, 2018 8:00am EST Benitec receives U.S. Orphan Drug Designation for BB-301, its ddRNAi therapeutic for the treatment of oculopharyngeal muscular dystrophy
Apr 04, 2017 8:00am EDT Key pre-clinical data on oculopharyngeal muscular dystrophy (OPMD) published in Nature Communications
Mar 13, 2017 6:00am EDT Benitec Biopharma completes second tranche placement to Nant Capital to raise A$5.45 million
Feb 16, 2017 8:00am EST Benitec Biopharma to present expanded data set from pivotal data in hepatitis B virus (HBV) in vivo model at International Liver Meeting in Shanghai, China
